Targeting Bombesin Peptide Receptors for Cancer Imaging: Perspective in Prostate, Lung and Breast Cancer

The rapid progression of the SARS CoV-2 pandemic, a respiratory disease also known as COVID-19, put forth a unique challenge for health care providers of balancing continuous cancer care with prevention of the continued spread of COVID-19 in immunosuppressed breast cancer patients. With these risks, cancer care required modifications as COVID-19 patients began to overwhelm hospitals. The American College Surgeons’ (ACS) COVID Pandemic Breast Cancer Consortium collaborated to form guidelines for interim cancer care therapy, stratifying urgency of care based on severity of diagnosis. NYC Health + Hospitals/Metropolitan (Metropolitan), a hospital located in East Harlem within the Manhattan borough of New York City, was located in the epicenter of the most severe initial outbreak of COVID-19. From March to June 2020, Metropolitan’s Breast Health Center (BHC) suspended cancer services including mammography and other diagnostic testing, chemotherapy treatments, and surgical procedures. Six (6) patients with known breast malignancies were followed closely during this time. The average age of these patients was 64.5 years old (range = 43-76 years), with one case under the age of 50. Two (2) of the patients were triple negative, two were ER/PR positive and HER2 negative, one (1) patient was ER positive and PR/HER2 negative, and one (1) patient was ER/PR positive and FISH negative. In this narrative, we reflect upon Metropolitan’s interim breast cancer care during March to June 2020 and suggest interventions and policies to better equip health systems to provide quality and continuous breast cancer care in future emergency circumstances.